The GBM AGILE trial recently released critical survival results for Regorafenib for Glioblastoma. Initially, earlier phase studies suggested potential benefits for this multikinase inhibitor in treating brain tumors. However, this large-scale registration trial failed to confirm survival advantages in newly diagnosed or recurrent settings. Consequently, these findings significantly impact how clinicians approach therapy for aggressive gliomas.

Clinical Outcomes of Regorafenib for Glioblastoma

Specifically, the trial enrolled patients with newly diagnosed unmethylated (NDU) and recurrent disease (RD). Participants received regorafenib or standard-of-care controls like temozolomide or lomustine. Furthermore, the statistical analysis utilized a Bayesian adaptive design to monitor efficacy closely. Unfortunately, the results showed median overall survival (OS) did not improve with regorafenib. For example, OS was 12.0 months in NDU patients compared to 13.7 months in the control group. Similarly, RD patients saw 8.0 months with regorafenib versus 9.2 months with lomustine.

Moreover, researchers noted increased toxicity levels in the regorafenib arm relative to the control arms. Because of these results, the drug did not meet the predefined criteria for superiority. Therefore, oncology guidelines have started removing regorafenib as a recommended option for recurrent glioblastoma. In summary, while the platform effectively tested the drug, regorafenib provides no survival benefit for these patients.

Frequently Asked Questions

What was the main finding of the GBM AGILE trial for regorafenib?

The trial found that regorafenib did not improve overall survival in patients with either newly diagnosed unmethylated or recurrent glioblastoma when compared to standard treatments.

How did regorafenib compare to standard treatments in terms of safety?

Notably, the regorafenib arm was associated with increased toxicity compared to the control treatments, which included temozolomide and lomustine.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.

References

Wen PY et al. Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial. J Clin Oncol. 2026 Apr 14. doi: 10.1200/JCO-25-01137. PMID: 41980234.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. 2026.